One out of 9 men will be diagnosed with prostate cancer during his lifetime. The U.S. Food and Drug Administration (FDA) has now approved the very first oral drug to treat the millions of men affected.
Myovant’s Orgovyx is aimed at treating advanced cases of the disease in a more convenient, effective way that minimizes the need for regular clinic visits, an especially appealing aspect to males, particularly during a global pandemic.
The Phase III study was conducted as an open-label trial with patients receiving either an Orgovyx pill daily or injections of Abbvie’s Lupron as an injection every three months. Because prostate cancer is fueled by testosterone production, both drugs decrease levels of the hormone in the body.